Updates in Pancreatic Cancer: Advances in Treatment and Research

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: September 11, 2017
Expiration Date: September 11, 2018

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Metastatic pancreatic cancer remains an illness with a very poor prognosis. There are approximately 50,000 new diagnoses, yet 40,000 deaths occur annually in the United States with this diagnosis. Mortality rates for other types of cancers are improving, whereas those for pancreatic cancers are not, and it is estimated to become the second leading cause of cancer-related death in the United States by the end of this decade. Dr. Alok Khorana, a leading expert in pancreatic cancer, shares his knowledge and insights in this activity as he highlights how the treatment and standard of care today is changing. To learn more about combination chemotherapy regimens for resected pancreatic cancer, the potential future role of immunotherapy in advanced pancreatic cancer, clinical trial updates in the neoadjuvant setting, and new guideline updates from the American Society of Clinical Oncology, view this engaging video to stay up to date with recent progress in this disease.

Target Audience

This activity is designed for multidisciplinary health care providers in the community setting, including oncologists, pharmacists, and associated multidisciplinary clinicians who may provide care to patients with pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Define criteria for resectable pancreas cancer as defined in 2016 guidelines
  • Summarize the current and emerging treatment approach to resectable pancreas cancer, including review of the 2017 updated recommendations on adjuvant therapy
  • Outline the current treatment paradigm for first- and second-line treatment of metastatic pancreatic cancer
  • Translate new clinical trial data and immunotherapy indication in pancreatic cancer patients with MSI high status

Agenda

Updates in Pancreatic Cancer: Advances in Treatment and Research – Alok A. Khorana, MD

Instructions for Participation and Credit

This activity is eligible for credit through September 11, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Alok A. Khorana, MD
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio

Dr. Alok Khorana received his medical degree from Maharaja Sayajirao University’s Medical College in Baroda (Gujarat), India. His postdoctoral training included a residency in internal medicine at the University at Buffalo in New York and a fellowship in hematology/oncology at the University of Rochester, New York. He is a Fellow of the American College of Physicians. Dr. Khorana is Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, the Sondra and Stephen Hardis Chair in Oncology Research, Vice-Chair for Clinical Services and Strategy of the Taussig Cancer Institute, and Director of the Gastrointestinal Malignancies Program at the Cleveland Clinic, Cleveland, Ohio.

Dr. Khorana is past chair of the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Panel (CPGC), chair of ASCO CPGC’s Pancreas Cancer Working Group, and co-chair of the ASCO Guidelines Panel on Resectable Pancreas Cancer. He also serves on the ASCO Scientific Program Committee and multiple ASCO guideline panels. He is past chair of the International Society on Thrombosis and Haemostasis Scientific Subcommittee on Hemostasis and Malignancy. In addition, he has previously served as a member of the US Pharmacopoeia Oncology Expert Committee. Dr. Khorana has been published in a variety of journals including New England Journal of Medicine, Journal of American Medical Association (JAMA), Journal of Clinical Oncology, Blood, Journal of the National Cancer Institute, Clinical Cancer Research, PLoS One, and JAMA Internal Medicine. He has co-authored chapters in multiple textbooks including Cecil Essentials of Medicine and DeVita’s Cancer: Principles and Practice of Oncology, and is co-editor of the book Cancer-Associated Thrombosis: New Findings in Translational Science, Prevention and Treatment.

Dr. Khorana’s clinical and translational research programs focus on predictive factors and drug development in gastrointestinal cancers and cancer-associated thrombosis and has been funded by grants from the National Cancer Institute, the National Heart, Lung, and Blood Institute, the Porter Family Fund, the Scott Hamilton CARES Initiative, and the V Foundation.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-168-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Alok Khorana has received honoraria as a consultant from Bayer AG, Janssen Pharmaceuticals, Inc., LEO Pharma Inc., Pfizer Inc., and Sanofi. He has received grant support related to research activities from Amgen Inc., Janssen, and LEO.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2017 MediCom Worldwide, Inc. All rights reserved